Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Desmopressin

Desmopressin

Desmopressin is a synthetic analogue of the natural hormone vasopressin, which is involved in regulating water balance and blood pressure.
It is commonly used to treat conditions such as diabetes insipidus, enuresis (bedwetting), and bleeding disorders.
Desmopressin works by increasing the reabsorption of water in the kidneys, leading to decreased urine output and increased fluid retention.
It has a longer half-life and is more potent than natural vasopressin, making it a valuable therapeutic option.
Researchers studying the effects and applications of desmopressin can utilize PubCompare.ai's AI-powered platform to optimize their research, identify the most effective protocols, and enhance the reproducibility and accuracy of their findings.

Most cited protocols related to «Desmopressin»

1
Cross-Sectional Study of VWD in the Netherlands
Cited 3 times
We performed a nationwide cross‐sectional study in patients with VWD in the Netherlands; the “Willebrand in the Netherlands” (WiN) study (de Wee et al, 2010, 2012). Patients with VWD were recruited between October 2007 and October 2009. The inclusion criteria were haemorrhagic symptoms or a family history of VWD, and historically lowest VWF antigen (VWF:Ag) and/or VWF ristocetin cofactor activity (VWF:RCo) ≤0·30 iu/ml and/or FVIII coagulant activity levels (FVIII:C) ≤0·40 iu/ml (for type 2N VWD). Patients were excluded if they had other haemostatic disorders. Blood and saliva samples were obtained at study inclusion.
For the current analyses, we excluded patients with type 3 VWD (defined as VWF levels <0·05 iu/ml and VWF propeptide (VWFpp) <0·05 iu/ml), because by definition there will be no increase of VWF levels in these patients (Sanders et al, 2015a). Furthermore, we excluded patients younger than 16 years old, patients with missing data on comorbidities, patients without centrally measured VWF levels or with centrally measured VWF levels during pregnancy, or desmopressin medication or clotting factor concentrate infusion 72 h prior to blood sampling. The study was performed according to the Declaration of Helsinki and approved by the Medical Ethical Committees of all participating centres. Informed consent was signed by all patients.
Atiq F., Meijer K., Eikenboom J., Fijnvandraat K., Mauser‐Bunschoten E.P., van Galen K.P., Nijziel M.R., Ypma P.F., de Meris J., Laros‐van Gorkom B.A., van der Bom J.G., de Maat M.P., Cnossen M.H, & Leebeek F.W. (2018). Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age‐related increase of VWF in von Willebrand disease. British Journal of Haematology, 182(1), 93-105.
Publication 2018
Antigens BLOOD Coagulants Complement factor H complement factor H, human Desmopressin Factor VIII-Related Antigen Hemorrhage Patients Pharmaceutical Preparations Pregnancy Saliva Vascular Hemostatic Disorders von Willebrand Disease, Type 3 Youth
2
Neuroimaging Study of 5-Year-Olds in FinnBrain Cohort
Cited 2 times
The participants are part of the FinnBrain Birth Cohort Study5 (Karlsson et al., 2018 (link)), where 5-year-olds were invited to neuropsychological, logopedic, neuroimaging, and pediatric study visits. For the neuroimaging visit, we primarily recruited participants that had a prior visit to neuropsychological measurements at circa 5 years of age (n = 141/146). However, there were a few exceptions: three participants were included without a neuropsychological visit, as they had an exposure to maternal prenatal synthetic glucocorticoid treatment (recruited separately for a nested case–control sub-study). The data additionally includes two participants that were enrolled for pilot scans. We aimed to scan all subjects between the ages 5 years 3 months and 5 years 5 months, and 135/146 (92%) of the participants attended the visit within this timeframe (reasons to scan outside the timeframe include, for example, the family moving the visit to a later date). The exclusion criteria for this study were: (1) born before gestational week 35 (before gestational week 32 for those with exposure to maternal prenatal synthetic glucocorticoid treatment), (2) developmental anomaly or abnormalities in senses or communication (e.g., blindness, deafness, and congenital heart disease), (3) known long-term medical diagnosis (e.g., epilepsy and autism), (4) ongoing medical examinations or clinical follow up in a hospital (meaning there has been a referral from primary care setting to special health care), (5) child use of continuous, daily medication (including per oral medications, topical creams, and inhalants. One exception to this was desmopressin (®Minirin) medication, which was allowed), (6) history of head trauma (defined as concussion necessitating clinical follow up in a health care setting or worse), (7) metallic (golden) ear tubes (to assure good-quality scans), and routine MRI contraindications.
In the current study, we used a subsample (approximately two thirds of the full sample) that consists of the participants that were scanned before a temporary stop to visits due to the restrictions caused by the coronavirus disease 2019 (COVID-19) pandemic. The scans were performed between 29 October, 2017 and 1 March, 2020. We contacted 415 families and reached 363 (87%) of them. In total, 146 (40% of the reached families) participants attended imaging visits (one pair of twins, one participant attended twice, and only the latter scan was included). Eight of them did not start the scan, and four were excluded due to excess motion artifact in the T1-image. Thereafter, 134 T1 images (mean age 5.34 years, SD 0.06 years, range 5.08–5.22 years, 72 boys, 62 girls) entered the processing pipelines. Supplementary Table 1 presents the demographic data as recommended in our earlier review (Pulli et al., 2019 (link)). A flowchart depicting the formation of the final sample through the different exclusion steps is presented in Figure 1.
Pulli E.P., Silver E., Kumpulainen V., Copeland A., Merisaari H., Saunavaara J., Parkkola R., Lähdesmäki T., Saukko E., Nolvi S., Kataja E.L., Korja R., Karlsson L., Karlsson H, & Tuulari J.J. (2022). Feasibility of FreeSurfer Processing for T1-Weighted Brain Images of 5-Year-Olds: Semiautomated Protocol of FinnBrain Neuroimaging Lab. Frontiers in Neuroscience, 16, 874062.
Full text: Click here
Publication 2022
Autistic Disorder BAD protein, human Birth Cohort Blindness Boys Brain Concussion Child Childbirth Congenital Abnormality Congenital Heart Defects COVID 19 Craniocerebral Trauma Desmopressin Diagnosis Epilepsy Follow-Up Care Glucocorticoids Inhalation Drug Administration Maternal Exposure Metals Minirin Mothers Pandemics Pharmaceutical Preparations Physical Examination Pregnancy Primary Health Care Radionuclide Imaging Twins Woman
3
Post-Operative Atrial Fibrillation Monitoring
Cited 2 times
Patient data including patient characteristics and medical history were assessed at the time of study inclusion and inserted into a predefined record abstraction form. Values of routine laboratory parameters were assessed at the time of hospital admission, immediately after surgery and prior to hospital discharge. Levels of NT‐proBNP were assessed daily during the hospital stay to elucidate the baseline level and the maximum increase after surgery in accordance to the local laboratory standards of the Medical University of Vienna (Roche Diagnostics, Switzerland).
Patients were continuously followed during the entire hospitalization including peri‐ and post‐operative care at both the intensive care unit (ICU) and normal ward. Peri‐ and post‐operative patient data were obtained via predefined case record forms. The peri‐ and post‐operative fluid management was screened in 24‐hour intervals after the index surgical event. Patients were screened for the transfusion of red blood cells (RBC), platelets, fresh frozen plasma (FFP), prothrombin complex concentrates (PCC), fibrinogen, anti‐thrombin III (AT‐III) and desmopressin. The respective individual fluid balance at the ICU 24 hours after the surgical procedure was calculated and validated by study personnel.
To ascertain the onset of an episode of AF after surgery, all participants received a permanent 6‐lead surface ECG monitoring until discharge. Electronic ECG tracings of all individuals were continuously screened. AF episodes were documented and validated via a 12‐lead surface ECG. POAF was defined in accordance to the guidelines of the European Society of Cardiology as a new onset of atrial fibrillating impulses (usually self‐terminating) after major cardiac surgery in patients that were in sinus rhythm before surgical intervention.
Schnaubelt S., Pilz A., Koller L., Kazem N., Hofer F., Fleck T., Laufer G., Steinlechner B., Niessner A, & Sulzgruber P. (2020). The impact of volume substitution on post‐operative atrial fibrillation. European Journal of Clinical Investigation, 51(5), e13456.
Publication 2020
Amino-terminal pro-brain natriuretic peptide Blood Platelets Cardiovascular System Desmopressin Diagnosis Electrocardiography, 12-Lead Europeans Fibrinogen Fluid Balance Heart Atrium Hospitalization Operative Surgical Procedures Patient Discharge Patients Plasma, Fresh Frozen Postoperative Care prothrombin complex concentrates Red Blood Cell Transfusion Sinuses, Nasal Surgical Procedure, Cardiac Thrombin
4
Platelet Transfusion Regimens for Surgery
Cited 2 times
We will include RCTs, non-RCTs and controlled before-after studies (CBAs) comparing three types of platelet transfusion regimens.
Comparison 1:. Prophylactic platelet transfusion prior to surgery versus no prophylactic platelet transfusion prior to surgery (placebo or no treatment).
Comparison 2: Prophylactic platelet transfusion prior to surgery versus alternative treatments (cryosupernatant, antifibrinolytics, thrombopoietin (TPO) mimetics). In this review we will exclude trials that assess the use of recombinant factor VIIa (rFVIIa); fibrinogen concentrate, recombinant factor XIII (rFXIII), prothrombin complex concentrate, and desmopressin as these are the subject of other Cochrane reviews that compared these interventions to an active comparator in people requiring a surgical procedure (Desborough 2017 (link); Fabes 2013 (link); Simpson 2012 (link)).
Comparison 3: Different platelet count thresholds for administering a prophylactic platelet transfusion prior to surgery.
We will record type of platelet component and dose of platelet component received.
Estcourt L.J., Malouf R., Doree C., Trivella M., Hopewell S, & Birchall J. (2017). Prophylactic platelet transfusions prior to surgery for people with a low platelet count. The Cochrane Database of Systematic Reviews, 2017(9), CD012779.
Publication 2017
Antifibrinolytic Agents Blood Platelets Condoms Desmopressin Factor IX Complex Factor XIII Fibrinogen Operative Surgical Procedures Placebos Platelet Counts, Blood Platelet Transfusion recombinant FVIIa Thrombopoietin Treatment Protocols
5
Cardiac Surgery Outcome Predictors
Cited 2 times
Preoperative patient data (age, weight, height, sex, BIA, European system for cardiac operative risk evaluation [EuroSCORE], diagnosis, preoperative myocardial infarction within 24 hours [MCI], history of asthma bronchiale, chronic obstructive pulmonary disease [COPD], insulin or non-insulin-dependent diabetes mellitus [IDDM, NIDDM], history of chronic kidney disease [CKD], dialysis, left ventricular ejection fraction [LVEF], stable and unstable angina pectoris, cardial decompensation, peripheral arterial obstructive disease [PAOD], and arterial hypertension), surgery-related factors (kind of operation, duration of anaesthesia and surgery duration of CPB and aortic cross-clamp [AoCC], unplanned insertion of assist devices, amount of fluids [cristalloids or colloids], need of catecholamines [noradrenalin, dobutamin, levosimendan, vasopressin, or milrinon], and need of blood products [erythrocytes, fresh frozen plasma, or thrombocytes] or coagulation factors [fibrinogen, prothrombin complex concentrate, desmopressin, or recombinant factor VIIa]), intraoperative diuresis and postoperative data (use of catecholamines, BIA, length of stay on intensive care unit [LOS-ICU], length of mechanical ventilation, or need of extracorporeal membrane oxygenation [ECMO]) were collected by a case report form.
Bernardi M.H., Rinoesl H., Dragosits K., Ristl R., Hoffelner F., Opfermann P., Lamm C., Preißing F., Wiedemann D., Hiesmayr M.J, & Spittler A. (2016). Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent. Critical Care, 20, 96.
Full text: Click here
Publication 2016
Anesthesia Angina, Unstable Aorta Arterial Occlusive Diseases Asthma BLOOD Blood Coagulation Factor Blood Platelets Cardia Catecholamines Chronic Kidney Diseases Chronic Obstructive Airway Disease Colloids Desmopressin Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent Diagnosis Dialysis Diuresis Dobutamine Erythrocytes Europeans Extracorporeal Membrane Oxygenation Factor IX Complex Fibrinogen Heart High Blood Pressures Hormone, Antidiuretic Insulin Levosimendan Mechanical Ventilation Medical Devices Myocardial Infarction Norepinephrine Operative Surgical Procedures Patients Peripheral Vascular Diseases Plasma, Fresh Frozen recombinant FVIIa Ventricular Ejection Fraction

Most recents protocols related to «Desmopressin»

1
Standardized Assessment of Bleeding and Joint Status in Nonsevere Hemophilia

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Adult Ankle Arthropathy Blood Coagulation Disorders Blood Transfusion Central Nervous System Coxa Desmopressin Epistaxis Health Personnel Hemarthrosis Hematuria Hemophilia A Joints Joints, Elbow Knee Muscle Tissue Operative Surgical Procedures Pain Measurement Patients Physical Examination Shoulder Therapy, Hormone Replacement Tooth Extraction Wounds Wounds and Injuries
2
Bilateral Inferior Petrosal Sinus Sampling for Diagnosing Cushing's Disease
Patients with positive LDDST results received BIPSS. Two 5-French hydrophilic-coated vertebral catheters were used to reach the bilateral petrosal sinuses. The catheters were first introduced into the left and right femoral veins using the Seldinger technique under local anaesthesia (Fig. 2A). Once the catheters were placed in the petrosal sinuses, contrast medium was injected to confirm their position (Fig. 2B, C). The ideal location of the catheters was the tip at the junction of the vertical and horizontal segments of the inferior petrosal sinus. All patients were successfully catheterized via the bilateral inferior petrosal sinuses. Blood samples (8 mL) were collected simultaneously from the right and left catheters and the femoral vein at 0 min (basal level), 5 and 10 min (peak levels) after the administration of 10 µg desmopressin. A ratio of central to peripheral prolactin gradient of 2.0 or greater was also used to verify the correct positioning of the catheter. The ratio of ACTH level in BIPSS to the level of femoral vein samples collected simultaneously was calculated before and after stimulation to diagnose CD. Any side effects during the procedure, such as hypertension, hypotension, bradycardia, tachycardia, headache, internal jugular vein thrombosis, earache, fall in SpO2, nausea, pain in the abdomen, and flushing, were documented.

Venography of inferior petrosal sinuses. a Puncture of the right femoral vein using the Seldinger technique. b Well-positioned catheters within the inferior petrosal sinuses (black arrows). c Right inferior petrosal sinus venography during contrast medium injection. The black arrows indicate the inferior petrosal sinus draining directly into the right internal jugular vein

Mao J.N., Yan H.Y., Chen J.Y., Yan C.L., Li P., Jin W, & Hang C.H. (2023). Comparison of the preoperative diagnostic accuracy of BIPSS versus MRI for Cushing disease: a single-centre experience. BMC Endocrine Disorders, 23, 42.
Full text: Click here
Publication 2023
Abdominal Pain Aftercare BLOOD Catheters Contrast Media Desmopressin Diagnosis Earache Femur Fistula Headache High Blood Pressures Jugular Vein Local Anesthesia Nausea Patients Phlebography Prolactin Punctures Saturation of Peripheral Oxygen Sinuses, Nasal Vein, Femoral Venipuncture Venous Thrombosis Vertebra
3
Generation of Kidney Tubuloids from Mice
Kidneys from 2 C57BL/6 mice (hereafter referred to as tubuloid line A and B) were digested by 1 μg/mL collagenase (LS004194, Worthington) treatment for 1.5 h to obtain tubular fragments. Fragments were embedded in Cultrex reduced growth factor Basement Membrane Extract (BME) type 2 (3533-001-02, R&D Systems) and cultured in expansion medium (EM) consisting of basal medium (BM) (advanced DMEM/F12 (12634028, Thermo Fisher Scientific) supplemented with 1% (v/v) penicillin/streptomycin, 1% (v/v) HEPES (H3375, Sigma-Aldrich) and 1% (v/v) GlutaMAX (35050038, Thermo Fischer Scientific) with 1.5% (v/v) B-27 supplement (17504044, Gibco), 1% (v/v) RSPO3-Fc fusion protein conditioned medium (R001, U-Protein Express BV), N-acetylcysteine (1 mM, A7250, Sigma-Aldrich), FGF-10 (100 ng/mL, 100-26, Peprotech), A 83-01 (5 μM, SML0788, Sigma-Aldrich), EGF (50 ng/mL, AF-100-15, Peprotech) and Y-27632 (10 μM, HY-10583, MedChem Express) (Table 1). Tubuloids were kept at 37°C with 5% CO2 and medium was changed three times per week. Tubuloids were passaged 1:2 to 1:3 weekly by mechanical shearing with a flame-polished pipette (Gijzen et al., 2021 (link)). Tubuloid CD differentiation medium (CM) consisted of BM supplemented with forskolin (10 μM, F6886, Merck), A 83-01 (5 μM, SML0788, Merck) and PD0325901 (1 μM, S1036, Pfizer) (Table 1). Tubuloid desmopressin (DDAVP) stimulation medium consisted of BM supplemented with DDAVP (10 nM, V1005, Sigma-Aldrich), A 83-01 (5 μM) and PD0325901 (1 μM) (Table 1).
Olde Hanhof C.J., Dilmen E., Yousef Yengej F.A., Latta F., Ammerlaan C.M., Schreurs J., Hooijmaijers L., Jansen J., Rookmaaker M.B., Orhon I., Verhaar M.C, & Hoenderop J.G. (2023). Differentiated mouse kidney tubuloids as a novel in vitro model to study collecting duct physiology. Frontiers in Cell and Developmental Biology, 11, 1086823.
Full text: Click here
Publication 2023
Acetylcysteine Colforsin collagenase 1 Culture Media, Conditioned DDAVP Desmopressin FGF10 protein, human Growth Factor HEPES Kidney Membrane, Basement Mice, Inbred C57BL PD-0325901 Penicillins Proteins Streptomycin Y 27632
4
Predictive Correction for Hyponatremia
We reviewed the correction method (predictive correction for future serum [Na] using the formula based on the Edelman equation, isotonic saline, hypertonic saline [bolus or continuous infusion], loop diuretics, vasopressin receptor antagonists, desmopressin, and intravenous or oral electrolyte repletion [including potassium (K), magnesium, calcium, and phosphorus]), and the number of serum [Na] measurements within 24 and 48 h after corrective therapy initiation. Cases that were administered the target infusate volume calculated using the predictive formula, as documented by the physicians, were allocated to the predictive equation use group. Regarding the predictive correction for future serum [Na], we used Eq. (2)18 (link). To determine the appropriate fluid composition and volume that corresponded to substantial urine loss, we applied the following infusate and fluid loss formula based on the Edelman Equation22 (link),37 (link): Serum[Na]2=(serum[Na]1×TBW1+Δ[Na+K])/(TBW1+ΔTBW)
Here, serum [Na]1 represents the current serum [Na], and serum [Na]2 represents the future serum [Na]. All data sources pertaining to the input and output of Na, K, and water (including infusion, urine, food, drink, drainage [Na, K, and water], electrolyte repletion [Na, K], and insensible evaporation [water]) were collected to optimize the accuracy of serum [Na]2 predictions via Eq. (3) (Supplementary Fig. 1).
After the diagnosis of hyponatremia, the output of Na, K, and water was calculated by examining spot urine and estimating the loss volume of urine and insensible excretion. We then calculated how much serum [Na] would change by taking Na, K, and water orally or intravenously and initiated treatment to achieve the target correction rate. To predict the future urine output of Na, K, and water, we used data from the most recent time point for urine [Na], urine [K], and the amount of urine flow, as we also concurrently performed spot urine tests for each blood test. In the case of diuretic therapy for hypervolemic hyponatremia, such as in heart failure, we estimated urine [Na], urine [K], and the amount of urine flow after diuretic administration and included them in the calculation. As it was challenging to predict urine volume at the beginning of the correction, we roughly estimated it. We considered the amount of water and sodium losses via perspiration negligible in typical cases; therefore, we did not take perspiration into account for the predictive correction38 ,39 (link). In cases with a sudden and substantial dilution of urine or rapid increase in serum [Na], desmopressin or hypotonic solution was administered at the discretion of the physicians to prevent overcorrection15 (link),16 (link),29 (link). The incidence of ODS, as well as the length of hospital stay and in-hospital mortality rate, were also evaluated.
Nagase K., Watanabe T., Nomura A., Nagase F.N., Iwasaki K., Nakamura Y., Ikai H., Yamamoto M., Murai Y., Yokoyama-Kokuryo W., Takizawa N., Shimizu H, & Fujita Y. (2023). Predictive correction of serum sodium concentration with formulas derived from the Edelman equation in patients with severe hyponatremia. Scientific Reports, 13, 1783.
Full text: Click here
Publication 2023
Calcium, Dietary Desmopressin Diagnosis Diuresis Diuretics Drainage Electrolytes Food Heart Failure Hematuria Hyponatremia Hypotonic Solutions Loop Diuretics Magnesium Phosphorus Physicians Potassium Saline Solution Saline Solution, Hypertonic Serum Sodium Sweat Technique, Dilution Therapeutics Urine Vasopressin Antagonist
5
Correcting Hyponatremia: Factors and Outcomes
Categorical and continuous data are presented as total numbers (percentages) and medians with Chi-square test or Fisher’s exact test as appropriate. For continuous variables, we used the Mann–Whitney U test. Logistic regression was used to identify independent potencial factors for appropriate correction of hyponatremia. Known risk factors (younger age, female sex, low BMI, solid tumor, low CCI, low initial serum [Na], low serum [K], low urine [Na], and low urine osmolality) for inappropriate correction and factors that were deemed important (cause of hyponatremia [drug-induced, unidentified cause], daily use of thiazide diuretics, the correction method [Edelman equation], number of serum [Na] measurements during the first 24 and 48 h, isotonic saline, hypertonic saline bolus and continuous infusion, electrolyte repletion, desmopressin, and kidney specialist intervention]) were included with or without P < 0.0528 (link)–30 (link). Separate analyses for undercorrection versus non-undercorrection and overcorrection versus non-overcorrection were also performed. All statistical analyses were performed using SPSS Statistics (version 22; IBM Japan, Tokyo, Japan).
Nagase K., Watanabe T., Nomura A., Nagase F.N., Iwasaki K., Nakamura Y., Ikai H., Yamamoto M., Murai Y., Yokoyama-Kokuryo W., Takizawa N., Shimizu H, & Fujita Y. (2023). Predictive correction of serum sodium concentration with formulas derived from the Edelman equation in patients with severe hyponatremia. Scientific Reports, 13, 1783.
Full text: Click here
Publication 2023
Desmopressin Electrolytes Females Hyponatremia Kidney Neoplasms Pharmaceutical Preparations Saline Solution Saline Solution, Hypertonic Serum Thiazide Diuretics Urine Youth

Top products related to «Desmopressin»

1
Ddavp by Merck Group
Sourced in United States
DDAVP is a synthetic antidiuretic hormone that acts to increase water reabsorption in the kidneys. It is a laboratory product used for research and analytical purposes.
2
Desmopressin by Bio-Techne
Sourced in United Kingdom
Desmopressin is a synthetic analogue of the natural antidiuretic hormone vasopressin. It is primarily used in the treatment of central diabetes insipidus and nocturnal enuresis.
3
Ain 76 by Bio-Serv
Sourced in United States
The AIN-76 is a laboratory equipment product designed for research and analysis purposes. It serves as a core component for various scientific applications. The detailed specifications and functionality of the AIN-76 are not available in this response, as providing an unbiased and factual description while maintaining conciseness is not possible.
4
Opc41061 by Merck Group
OPC41061 is a laboratory equipment product manufactured by Merck Group. It is designed to facilitate scientific research and analysis. The core function of this product is to provide a reliable and precise measurement tool for researchers and laboratory professionals. No further details about the intended use or interpretation of this product are provided.
5
Evom2 epithelial voltohmmeter by World Precision Instruments
Sourced in United States, United Kingdom, Germany
The EVOM2 Epithelial Voltohmmeter is a laboratory instrument designed to measure the transepithelial electrical resistance (TER) and short-circuit current (Isc) of cell monolayers grown on permeable supports. It provides accurate measurements of these parameters, which are important indicators of the integrity and function of epithelial cell barriers.
6
Desmopressin ddavp by Merck Group
Sourced in Italy
Desmopressin (dDAVP) is a synthetic analog of the natural antidiuretic hormone vasopressin. It is used as a laboratory reagent to study water and electrolyte balance in biological systems. Desmopressin acts on the V2 receptors in the kidneys to increase water reabsorption, leading to decreased urine output. This property makes it a useful tool for researchers investigating fluid homeostasis and related physiological processes.
7
Alzet model 2002 by Durect
Sourced in United States
The Alzet model 2002 is a miniature, implantable osmotic pump designed for continuous and controlled delivery of substances in laboratory animals. The device is capable of delivering substances at a constant rate for up to 2 weeks.
8
8 br camp by Merck Group
Sourced in United States, Germany, United Kingdom
8-Br-cAMP is a laboratory reagent used in biochemical and cell biology research. It is a synthetic analog of the naturally occurring cellular signaling molecule cyclic AMP (cAMP). 8-Br-cAMP is used as a tool to study the effects of cAMP signaling in various cellular processes.
9
Ecl reagent by PerkinElmer
Sourced in United States, Japan, Canada, Germany
ECL reagent is a chemiluminescent detection system used in Western blotting and other immunoassays. It provides a sensitive and quantitative method for detecting proteins labeled with specific antibodies.
10
Dmem f12 by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Denmark, Israel, Macao, Ireland, Netherlands, Austria, Hungary, Holy See (Vatican City State), Sweden, Brazil, Argentina, India, Poland, Morocco, Czechia
DMEM/F12 is a cell culture medium developed by Thermo Fisher Scientific. It is a balanced salt solution that provides nutrients and growth factors essential for the cultivation of a variety of cell types, including adherent and suspension cells. The medium is formulated to support the proliferation and maintenance of cells in vitro.

More about "Desmopressin"

Desmopressin, a synthetic analogue of the natural hormone vasopressin, is a versatile and widely used therapeutic agent.
It plays a crucial role in regulating water balance and blood pressure, making it an important treatment option for conditions like diabetes insipidus, enuresis (bedwetting), and bleeding disorders.
Desmopressin works by increasing the reabsorption of water in the kidneys, leading to decreased urine output and increased fluid retention.
Compared to natural vasopressin, it has a longer half-life and is more potent, making it a valuable tool for clinicians and researchers.
When studying the effects and applications of desmopressin, researchers can leverage the power of PubCompare.ai's AI-powered platform.
This innovative tool helps optimize research, identify the most effective protocols, and enhance the reproducibility and accuracy of findings.
Beyond desmopressin, researchers may also encounter related terms and concepts, such as DDAVP (a brand name for desmopressin), AIN-76 (a type of animal diet), OPC41061 (a related compound), EVOM2 Epithelial Voltohmmeter (a device used in research), 8-Br-cAMP (a chemical compound), and ECL reagent (a tool used in biochemical analysis).
By understanding the broader context and leveraging the insights provided by PubCompare.ai, researchers can unlock the full potential of their desmopressin studies, leading to more robust and impactful findings.
Teh platform's data-driven approach ensures that researchers can make informed decisions, leading to enhanced reproducibility and accuracy in their work.